PURPOSE OF REVIEW: This review focuses on the associations between the renin-angiotensin system, hypertension, and severe acute respiratory syndrome (SARS-COV-2) infection . A brief prelude on the current state of affairs with COVID-19 is given . In addition to an overview of ACE2, Ang II, and Ang (1-7), this review presents a brief statement on hypertension, including the function of enzymes involved in the control of hypertension, cardiovascular disease, diabetes mellitus, and other malignancies .
RECENT FINDINGS: There is currently no data in support of the concerns raised with the use of ACEIs/ARBs . Many researchers have voiced concerns that the use of ACEIs and ARBs may increase tissue ACE2 levels . These researchers therefore recommend that individuals on ACEIs/ARB's medications withhold such antihypertensive drugs, unless advised by their physicians to do so . SARS-CoV-2 uses ACE2 receptors as the port of entry to human hosts . ACE2 and ACE are different enzymes and ACE inhibitors do not inhibit ACE2 . Therefore, the use of ARB's or ACEIs should not be discontinued if an individual is infected by SARS-CoV-2 . Further studies are required to investigate the effect of ACEIs and ARBs on ACE2 expression and COVID-19.
Index: Angiotensin II, Angiotensin-converting enzyme inhibitors, Hypertension, Renin-angiotensin system, SARS-COV-2